Ivan Cornella-Taracido

Ivan Cornella-Taracido has a strong background in chemical biology and proteomics, with over 20 years of experience in the pharmaceutical industry. Ivan currently serves as the Chief Scientific Officer at Covant Therapeutics, where they oversee the company's scientific strategy. Prior to joining Covant Therapeutics, Ivan held the position of Vice President of Translational Chemical Biology at Roivant Sciences, where they contributed to the development of innovative therapies. Ivan also served as the VP of Proteomics and Chemical Biology at Cedilla Therapeutics, where they focused on advancing proteomics technology for drug discovery. Ivan has held various leadership positions at major pharmaceutical companies, including Merck, AstraZeneca, Sanofi, and Novartis Institutes for BioMedical Research. Ivan'sexpertise lies in target identification and validation chemistry, chemical genetics, and chemical proteomics. Ivan obtained their graduate degree in chemistry and conducted research at BASF and Solvay Pharmaceuticals B.V.

Ivan Cornella-Taracido's education history includes four significant academic experiences. From 2014 to 2018, they attended the MIT Sloan Executive Degree Program, where they obtained an Executive Development Certificate in Strategy and Innovation. The focus of their studies there was on strategy and innovation. Earlier in their education, from 2004 to 2004, Ivan pursued a postdoctoral program at Harvard Medical School, specializing in Chemical Biology. Prior to that, they attended Boston College from 2002 to 2003 for another postdoctoral program, with a focus on Chemistry. Ivan's academic journey began at Universidade da Coruña, where they pursued their Ph.D. in Chemistry from 1997 to 2001.